| Rheumatoid Arthritis
Kevzara vs Kineret
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Kevzara vs Kineret with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKineret has a higher rate of injection site reactions vs Kevzara based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kineret but not Kevzara, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kevzara
Kineret
At A Glance
SC injection
Every 2 weeks
IL-6 receptor antagonist
SC injection
Daily
IL-1 receptor antagonist
Indications
- Rheumatoid Arthritis
- Polymyalgia Rheumatica
- Juvenile polyarthritis
- Rheumatoid Arthritis
- Chronic Infantile Neurological, Cutaneous, and Articular Syndrome
- INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
Dosing
Rheumatoid Arthritis 200 mg SC injection once every 2 weeks; may be used as monotherapy or in combination with methotrexate or other conventional DMARDs.
Polymyalgia Rheumatica 200 mg SC injection once every 2 weeks in combination with a tapering course of corticosteroids; may be used as monotherapy following discontinuation of corticosteroids.
Juvenile polyarthritis 200 mg SC injection once every 2 weeks for patients weighing 63 kg or greater; may be used as monotherapy or in combination with conventional DMARDs.
Rheumatoid Arthritis 100 mg/day SC; administer every other day in severe renal insufficiency or ESRD (creatinine clearance <30 mL/min).
Chronic Infantile Neurological, Cutaneous, and Articular Syndrome Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; once daily or split into twice daily; administer every other day in severe renal insufficiency or ESRD.
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; administer every other day in severe renal insufficiency or ESRD.
Contraindications
- Known hypersensitivity to sarilumab or any of the inactive ingredients
- Known hypersensitivity to E. coli-derived proteins, anakinra, or any components of the product
Adverse Reactions
Most common (>=3%) Neutropenia, increased ALT, injection site erythema, upper respiratory tract infections, urinary tract infections
Serious Serious infections (pneumonia, cellulitis), gastrointestinal perforation, hypersensitivity reactions, neutropenia, thrombocytopenia, elevated liver enzymes, lipid abnormalities
Most common (>=5%) Injection site reaction, worsening of RA, upper respiratory tract infections, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain
Serious Serious infections (cellulitis, pneumonia, bone and joint infections), neutropenia (particularly in combination with TNF blocking agents), lymphoma, other malignancies
Postmarketing Transaminase elevations, non-infectious hepatitis, thrombocytopenia (including severe), DRESS, injection site amyloid deposits
Pharmacology
IL-6 receptor antagonist; sarilumab is a human recombinant IgG1 monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), inhibiting IL-6-mediated pro-inflammatory signaling involved in T-cell activation, acute phase protein synthesis, and joint inflammation.
IL-1 receptor antagonist; anakinra is a recombinant human IL-1Ra that competitively inhibits IL-1alpha and IL-1beta binding to the interleukin-1 type I receptor (IL-1RI), blocking downstream inflammatory and immunological responses including cartilage degradation and bone resorption.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kevzara
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Kineret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Kevzara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (2/8)
Kineret
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Humana
Kevzara
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Kineret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KevzaraView full Kevzara profile
KineretView full Kineret profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.